Being part of the first-ever global summit focused on the emerging technology and science revolutionizing oncology care, ASCO 2019 Breakthrough is being held on October 11-13, Bangkok, Thailand. Designed for innovators, thinkers, and early adopters of clinical change, this inaugural ASCO event, co-hosted by the Thai Society of Clinical Oncology in collaboration with society partners throughout the region, will leverage the best of technology, science, and medical practice to transform the future of cancer care.
SeekIn's study entitled "Development of a blood-based cancer screening assay with a novel multivariate cancer risk score (MCRS) model by integrating shallow WGS data and plasma tumor markers" is selected as one of the four oral presentations at the rapid abstract session. Grail will also present at the same session with their latest results from CCGA study.
SessionTitle: Rapid Abstract Session A: Molecular Diagnostics—Where are we at?
Session Type: Rapid Abstract Session
Date: Friday, October 11, 2019
Time: 1:45 PM - 2:30 PM
Location: Convention Centre A1
PresentationTime/Duration: 2:05 PM - 2:10 PM
This is the first time SeekIn presents their latest research on ASCO. Based on the study result, SeekIn also receives Abstract Award from the ASCO Foundation and the 2019 ASCO Breakthrough Program Committee.
Founder & CEO of SeekIn Inc., Dr. Mao Mao, is going to present the company's latest progress on development of blood-based cancer early detection test. A novel multivariate cancer risk score (MCRS) model that can effectively detect multiple cancer types by integrating shallow whole genome sequencing (sWGS) data from cell-free DNA (cfDNA) and protein markers data in a single blood draw has been developed by SeekIn. Two cancer genomic features, copy number variation (CNV) and fragment size from the sWGS data were explored in this particular study.
A total number of 466 participants (39 cancer patients, 427 non-cancer participants) were selected as a training set to establish MCRS model and cutoff value. An independent validation set consisting of 84 newly diagnosed and treatment-naive cancer patients (stage I-IV) and 338 normal individuals with no cancer diagnosis was utilized to evaluate the robustness of the MCRS model in distinguishing cancer cases from the normal individuals.
When CNV and protein marker results were integrated into the MCRS model, 45 out of 84 (53.6%) cancer cases were detected in the validation set, resulting in a PPV of 91.8% and specificity of 98.8%. Moreover, the performance of MCRS model was further improved by integrating additional fragment size feature. The MCRS model distinguished 63 of 84 (75.0%) cancer cases by incorporating fragment size analysis into the model, with a PPV of 94.0% , specificity of 98.8%, and an AUC of 0.972.
In conclusion, this study developed a blood-based multi-cancer detection assay by combining shallow WGS plus conventional protein markers. A MCRS model was established to integrate multiple cancer hallmarks (e.g.: CNV and fragment size) to improve the effectiveness of detecting multiple cancer types at very high specificity. It indicates a cost-effective, non-invasive cancer screening approach is a plausible complementary tool for cancer early diagnosis in clinical settings.
These new data will also be presented at Poster Session A: Access to Care, Diagnostics, Early Detection and Diagnosis, Prevention and Screening, and Surveillance
Poster ID Number: 45
Poster Board Number: A3
Poster Title: Development of a blood-based cancer screening assay with a novel multivariate cancer risk score (MCRS) model by integrating shallow WGS data and plasma protein markers
Date: Friday, October 11, 2019
Time: 11:45 AM - 1:45 PM 5:15 PM - 6:15 PM
Location: Convention Centre B1